NOXXON Pharma N.V. (ALNOX.PA)
- Business Wire
NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial With NOX-A12 in Brain Cancer Patients
BERLIN, January 07, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the Data Safety Monitoring Board (DSMB) positively evaluated safety data from the initial four weeks of treatment of the first patient enrolled in the GLORIA clinical trial expansion arm with NOX-A12 combined with radiotherapy and bevacizumab. The DSMB conclude
- Business Wire
NOXXON Provides Update on Evaluation of NOX-A12 in Non-Oncology Indication by a Leading International Pharma Company
BERLIN, January 05, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the evaluation of NOX-A12 by a leading international pharmaceutical company in a non-oncology indication announced on June 24, 2019 has been completed. The pharmaceutical company has decided not to pursue further work with NOX-A12 in this field and to terminate the collabora
- Business Wire
CORRECTING and REPLACING(1): NOXXON Secures €17 Million Expansion of Equity-linked Facility With Atlas to Advance NOX-A12 in Glioblastoma and Pancreatic Cancer Programs
BERLIN, January 03, 2022--Regulatory News: This press release corrects a prior version published on December 29, 2021 and is updated to include a corrected annex. The corrected press release reads:
